Levosimendan Reduces Mortality in Adults with Left Ventricular Dysfunction Undergoing Cardiac Surgery: A Systematic Review and Meta-analysis

Journal of Cardiac Surgery

Volumn 30, Issue 7, 2015, Pages 547-554

  Lim, Ju Yong ^a   Deo, Salil V ^b   Rababa'H, Abeer ^c   Altarabsheh, Salah E ^d   Cho, Yang Hyun ^e   Hang, Dustin ^f   McGraw, Michael ^g   Avery, Edwin G ^g   Markowitz, Alan H ^a   Park, Soon J ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Jordan)

^d King Hussein Medical Center Queen Alia Heart institute   (Jordan)

^e Samsung Advanced Institute of Technology (SAIT)   (South Korea)

^f CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INOTROPIC AGENT; LEVOSIMENDAN; CARDIOTONIC AGENT; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; HEART EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART SURGERY; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PEER REVIEW; POSTOPERATIVE COMPLICATION; SENSITIVITY ANALYSIS; STANDARDIZATION; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ACUTE KIDNEY INJURY; BIBLIOGRAPHIC DATABASE; CARDIAC OUTPUT, LOW; HEART LEFT VENTRICLE FUNCTION; POSTOPERATIVE COMPLICATIONS; PREVENTION AND CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ACUTE KIDNEY INJURY; ADULT; CARDIAC OUTPUT, LOW; CARDIAC SURGICAL PROCEDURES; CARDIOTONIC AGENTS; DATABASES, BIBLIOGRAPHIC; HUMANS; HYDRAZONES; POSTOPERATIVE COMPLICATIONS; PYRIDAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84934435001     PISSN: 08860440     EISSN: 15408191     Source Type: Journal    
DOI: 10.1111/jocs.12562     Document Type: Article

References (31)

1. Alvarez J, Taboada M, Rodriguez J, et al,: [Hemodynamic effects of levosimendan following cardiac surgery]. Revista espanola de anestesiologia y reanimacion 2005; 52: 389-94.
2. Labriola C, Siro-Brigiani M, Carrata F, et al,: Hemodynamic effects of levosimendan in patients with low-output heart failure after cardiac surgery. Int J Clin Pharmacol Therap 2004; 42: 204-11.
3. Landoni G, Mizzi A, Biondi-Zoccai G, et al,: Reducing mortality in cardiac surgery with levosimendan: A meta-analysis of randomized controlled trials. J Cardiothorac Vasc Anesth 2010; 24: 51-7.
4. Moher D, Liberati A, Tetzlaff J, et al,: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Int J Surg 2010; 8: 336-41.
5. Hozo SP, Djulbegovic B, Hozo I,: Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005; 5: 13.
6. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Colloboration; March 2011.
7. Duval S, Tweedie R,: Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000; 56: 455-463.
8. Eriksson O, Pollesello P, Haikala H,: Effect of levosimendan on balance between ATP production and consumption in isolated perfused Guinea-Pig heart before ischemia or after reperfusion. J Cardiovasc Pharmacol 2004; 44: 316-321.
9. Lahtinen P, Pitkanen O, Polonen P, et al,: Levosimendan reduces heart failure after cardiac surgery: A prospective, randomized, placebo-controlled trial. Crit Care Med 2011; 39: 2263-2270.
10. Levin R, Degrange M, Del Mazo C, et al,: Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Exp Clin Cardiol 2012; 17: 125-130.
11. Severi L, Lappa A, Landoni G, et al,: Levosimendan versus intra-aortic balloon pump in high-risk cardiac surgery patients. J Cardiothorac Vasc Anesth 2011; 25: 632-636.
12. Al-Shawaf E, Ayed A, Vislocky I, et al,: Levosimendan or milrinone in the type 2 diabetic patient with low ejection fraction undergoing elective coronary artery surgery. J Cardiothorac Vasc Anesth 2006; 20: 353-357.
13. Baysal A, Yanartas M, Dogukan M, et al,: Levosimendan improves renal outcome in cardiac surgery: A randomized trial. J Cardiothorac Vasc Anesth 2014; 28: 586-594.
14. De Hert SG, Lorsomradee S, Cromheecke S, et al,: The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesth Analg 2007; 104: 766-773.
15. Erb J, Beutlhauser T, Feldheiser A, et al,: Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. J Int Med Res 2014; 42: 750-764.
16. Gandham R, Syamasundar A, Ravulapalli H, et al,: A comparison of hemodynamic effects of levosimendan and dobutamine in patients undergoing mitral valve repair/replacement for severe mitral stenosis. Ann Card Anaesth 2013; 16: 11-15.
17. Jarvela K, Maaranen P, Sisto T, et al,: Levosimendan in aortic valve surgery: Cardiac performance and recovery. J Cardiothorac Vasc Anesth 2008; 22: 693-698.
18. Lehmann A, Kiessling AH, Isgro F, et al,: Levosimendan in patients with acute myocardial ischaemia undergoing emergency surgical revascularization. Eur J Anaesthesiol 2008; 25: 224-229.
19. Leppikangas H, Jarvela K, Sisto T, et al,: Preoperative levosimendan infusion in combined aortic valve and coronary bypass surgery. Br J Anaesth 2011; 106: 298-304.
20. Lomivorotov VV, Boboshko VA, Efremov SM, et al,: Levosimendan versus an intra-aortic balloon pump in high-risk cardiac patients. J Cardiothorac Vasc Anesth 2012; 26: 596-603.
21. Tritapepe L, De Santis V, Vitale D, et al,: Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. Br J Anaesth 2009; 102: 198-204.
22. Pierrakos C, Velissaris D, Franchi F, et al,: Levosimendan in critical illness: A literature review. J Clin Med Res 2014; 6: 75-85.
23. Lahtinen P, Pitkanen O, Musialowicz T,: Levosimendan increases bleeding risk after heart valve surgery: A retrospective analysis of a randomized trial. J Cardiothorac Vasc Anesth 2014; 28: 1238-1242.
24. Harrison RW, Hasselblad V, Mehta RH, et al,: Effect of levosimendan on survival and adverse events after cardiac surgery: A meta-analysis. J Cardiothorac Vasc Anesth 2013; 27: 1224-1232.
25. Michael Borenstein LVH, Julian Higgins PT, Hannah Rothstein R,: Introduction to meta-analysis. 2009; John Wiley & Sons, Ltd. United Kingdom.
26. Bradburn MJ, Deeks JJ, Berlin JA, et al,: Much ado about nothing: A comparison of the performance of meta-analytical methods with rare events. Stat Med 2007; 26: 53-77.
27. Nijhawan N, Nicolosi AC, Montgomery MW, et al,: Levosimendan enhances cardiac performance after cardiopulmonary bypass: A prospective, randomized placebo-controlled trial. J Cardiovasc Pharmacol 1999; 34: 219-228.
28. Ukkonen H, Saraste M, Akkila J, et al,: Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther 2000; 68: 522-531.
29. Husedzinovic I, Barisin S, Bradic N, et al,: Levosimendan as a new strategy during off-pump coronary artery bypass grafting: double-blind randomized placebo-controlled trial. Croat Med J 2005; 46: 950-6.
30. Oliveira MT, Jr., Follador W, Martins ML, et al,: [Cost analysis of the treatment of acute decompensated heart failure. Levosimendan versus dobutamine]. Arquivos brasileiros de cardiologia 2005; 85: 9-14.
31. Fedele F, D'Ambrosi A, Bruno N, et al,: Cost-effectiveness of levosimendan in patients with acute heart failure. J Cardiovasc Pharmacol 2011; 58: 363-366.